Navigation Links
New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Date:5/8/2009

BeniSILVER Study

BeniSILVER was a 14-15 week, prospective, open-label, single-arm, dose-titration, study to investigate the safety and BP-lowering efficacy of the proposed titration of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide in 178 patients age 65 years or older with mild to moderate (Stage 1) or challenging (Stage 2) hypertension. Following a 2-3 week placebo period, 176 patients started olmesartan (OM) 20 mg. If SBP remained greater than or equal to 120 mm Hg or DBP remained greater than or equal to 70 mm Hg, patients were titrated at 3-week intervals until BP was normalized as follows: OM 40mg, olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40mg/12.5mg and OM/HCTZ 40mg/25mg. Patients (asymptomatic) with BP <120/70 mm Hg continued on their current assigned dose (maintenance treatment) unless BP was uncontrolled, SBP greater than or equal to 140mm Hg and/or DBP greater than or equal to 90 mm Hg, at which time the titration schedule was resumed.

The primary endpoint was change in mean SBP from baseline after 12 weeks of treatment as measured by a 24-hour ABPM. The secondary endpoints included change from baseline in mean 24-hour ambulatory DBP, change from baseline in mean SeSBP and SeDBP and proportion of patients achieving BP goal (<140/90, <135/85, <130/80 & <120/80 mm Hg), at each titration period and study end and a subgroup analysis by age (greater than or equal to 75 years or >75 years). Mean baseline ABPM was 148.8/80.9 mm Hg and mean baseline seated BP was 165.5/87.7 mm Hg, indicating predominant systolic hypertension in this elderly patient cohort with a mean age of 71.9 years and 65.9 percent challenging (Stage 2) hypertension.

Treatment emergent adverse events (TEAE) were seen in 56 patients, 32.6% of the treatment population. The most common were dizziness (8 patients, 4.5%) diarrhea (4 patients, 2.2%), upper respiratory tract infection (4 patients, 2.2%)
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... Inc., a privately,held biopharmaceutical company that specializes ... ophthalmic,pharmaceuticals, today reported the interim month three ... pharmacokinetic (PK) study of Medidur(TM) FA,which Alimera ... Iluvien(TM),if approved by the U.S. Food and ...
... developing proposals to fund clinical studies for early detection ... ... 25 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ), a ... the Small,Business Innovation Research (SBIR) and Small Business Technology Transfer,(SBTT) seed ...
Cached Medicine Technology:Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 2Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 3Small Business Innovation Research Program Awards Grant to Biomoda 2
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Epigenetics finds ... science research, including oncology, drug discovery, developmental biology, and ... emerging as one of the most widely used techniques ... to GLOBOCAN, the prevalence of cancer is rapidly growing ... cases, 8.2 million cancer deaths, and 32.6 million people ...
(Date:12/24/2014)... Rosa, CA (PRWEB) December 24, 2014 New ... particularly susceptible to hearing loss related depression (March 6, 2014, ... associated with gradual hearing loss (about 50 percent according to ... extremely positive effect on how a person feels and relates ... report that overall improvements are also made by way of:, ...
(Date:12/24/2014)... Yunx.co.uk, a hot style dress supplier that offers all ... unveils 65 new bridesmaid dresses and announces ... to 80% off. , Yunx.co.uk’s dresses are very popular ... looks and delicate craftsmanship. These new bridesmaid dresses are ... and offering high-quality women’s dresses with fast delivery to ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... sex for one year will be allowed to donate blood in ... a 31-year ban on donations from men who have sex with ... intention to release a new draft guidance in early 2015 that ... The FDA is changing its policy based on data from ...
Breaking Medicine News(10 mins):Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
... for people with neurological disorders , TUESDAY, Oct. 20 ... can promote memory, social behavior and communication in patients ... music works in the human brain to improve mental ... , Now, new research in monkeys suggests that humans, ...
... solutions for the comprehensive analysis of Next Generation Sequencing ... Molecular Life Sciences (NCMLS) installed a Genomatix Genome Analyzer ... in transcription factor analysis and epigenetic research, is full ... a member of EMBO. The Genomatix Genome Analyzer ...
... What: Presenting research on the latest issues and ... Communications, ASN Press Briefings, and related symposia will ... Convention Center, San Diego, California ... is Independently Associated with Elevated Blood Pressure. Findings ...
... Wall posts, photo tags and questionnaires are used ... help friends and families connect; Produce for Kids, ... utilizing Facebook to assess your fresh produce personality. ... Play with Your Produce Personality Quiz helps ...
... experts Kenneth J. Doka, PhD, MDiv, and Sherry R. ... grieving people cope with the holidays during Hospice Foundation ... 16 from 1pm-2pm EST. , "Facing loss at any ... the holidays, traditionally times filled with joy and celebration, ...
... , TUESDAY, Oct. 20 (HealthDay News) --,New research links high ... than average, suggesting that advanced bone age may predict cardiovascular ... the journal Hypertension , looked at children and found ... their chronological age within four months. , But in ...
Cached Medicine News:Health News:The Brain Comes Alive With the Sounds of Music 2Health News:Press alert for American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition 2Health News:Is Your Fresh Produce Personality Bananas ? 2Health News:Hospice Foundation of America Presents Webinar on 'Grief, Holidays, and Family Dynamics' 2Health News:Clues to Hypertension in Kids May Be Seen in Bones 2
... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ... required for large and small joint arthroscopic ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
Medicine Products: